Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACmono LT long-term follow-up
NL-OMON60723Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2025
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of tacrolimus, mycophenolate mofetil and 23-valent pneumococcal polysaccharide vaccine (2 arms), sponsored by Erasmus MC. Primary endpoint: Uncensored graft survival. Started Jan 2025; status: recruiting.
02
Drugs
tacrolimusmycophenolate mofetil23-valent pneumococcal polysaccharide vaccine
Beyond the preview
Go deeper on NL-OMON60723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60723.